ReliaTech

Executive Summary

ReliaTech GmbH is a Berlin-based manufacturer of high-quality research reagents, specializing in recombinant proteins, monoclonal and polyclonal antibodies for angiogenesis and lymphangiogenesis research. Founded in 2018, the company is ISO9001:2015 certified and emphasizes its 'Made in Germany' production and expert customer support. Serving the life science research market with a focus on cytokines and growth factors, ReliaTech operates in a niche but competitive segment of the antibody and protein supply industry. The company is privately held with no disclosed funding or valuation, and its limited public profile suggests it is in an early commercial stage. ReliaTech's success hinges on its ability to differentiate through quality and customer service, but without clear growth indicators or strategic updates, its near-term trajectory remains uncertain. The company may benefit from the broader trend of increasing research spending, but faces intense competition from larger, well-established suppliers.

Upcoming Catalysts (preview)

• Q2 2027Expansion of product portfolio into oncology-related antibodies40% success
• Q4 2026Strategic partnership with a major life science distributor25% success
• Q1 2027ISO certification renewal or upgrade (e.g., ISO13485) for diagnostic applications50% success